Financial Performance - Revenue for the Reporting Period was approximately HK$346.9 million, a decrease from HK$357.8 million in the same period last year, representing a decline of 3.1%[8]. - Profit after taxation for the Reporting Period amounted to approximately HK$17.1 million, compared to a loss of HK$8.7 million in the previous year[11]. - Basic earnings per share for the Reporting Period was approximately 2.83 HK cents, a significant improvement from a loss of 1.05 HK cents per share in the same period last year[11]. - Gross profit for the Reporting Period was approximately HK$49.6 million, up from HK$48.8 million in the previous year, indicating a slight increase of 1.5%[11]. - Total comprehensive income for the period was HK$16.0 million, compared to a total comprehensive expense of HK$9.6 million in the previous year[13]. - The company reported a profit before taxation of approximately HK$19.3 million, a turnaround from a loss of HK$8.2 million in the same period last year[11]. - The Group's total profit before taxation for the six months ended 30 September 2024 was HK$19,302,000[34]. - The Group's profit before taxation for the six months ended 30 September 2024 was HK$14,684,000, compared to a loss of HK$5,235,000 in the same period of 2023[55]. Revenue Breakdown - Revenue from trading of apparel products was HK$244,981,000, down 10.9% from HK$274,964,000 in the previous year[31]. - Revenue from healthcare products trading and leasing of medical devices totaled HK$73,408,000, an increase of 12.5% from HK$65,060,000 in 2023[31]. - The Garment Business generated revenue of HK$244,981,000, while the Healthcare Products Business contributed HK$73,408,000 for the six months ended 30 September 2024[34]. - Revenue from major customers contributing over 10% of total revenue was HK$148,419,000 for the six months ended 30 September 2024, down from HK$154,349,000 in 2023[44]. - Revenue from the Healthcare Products Business increased by approximately HK$8.3 million or 12.8%, from approximately HK$65.1 million for the six months ended 30 September 2023 to approximately HK$73.4 million for the Reporting Period[129]. Expenses and Costs - Selling and distribution expenses decreased to HK$20.2 million from HK$25.5 million, a reduction of 20.5% year-over-year[11]. - Research and development expenses for the Reporting Period were approximately HK$7.4 million, down from HK$11.4 million in the previous year, reflecting a decrease of 35.5%[11]. - Administrative expenses charged by related companies amounted to HK$3,350,000, down from HK$4,572,000 in the prior year[83]. - Finance costs increased to approximately HK$4.7 million from HK$3.2 million, primarily due to factoring costs from the Garment Business[151]. Assets and Liabilities - As of September 30, 2024, total assets amounted to HK$ 253,834,000, an increase of 19.7% from HK$ 211,929,000 as of March 31, 2024[15]. - The net current assets increased significantly to HK$ 74,662,000, compared to HK$ 6,899,000 as of March 31, 2024, reflecting a substantial improvement in liquidity[15]. - Total equity increased to HK$ 176,198,000 as of September 30, 2024, up from HK$ 138,182,000 as of March 31, 2024, indicating strong financial health[17]. - Current liabilities increased to HK$ 179,172,000 as of September 30, 2024, from HK$ 205,030,000 as of March 31, 2024, reflecting improved management of short-term obligations[15]. - Total consolidated assets as of 30 September 2024 were HK$474,950,000, an increase from HK$429,885,000 as of 31 March 2024[38]. - Total consolidated liabilities as of 30 September 2024 were HK$298,752,000, compared to HK$291,703,000 as of 31 March 2024[38]. Cash Flow - Operating cash flows before working capital changes were HK$ 15,122,000, a significant improvement from HK$ 1,397,000 in the previous year[26]. - The company experienced a net cash used in operating activities of HK$ 6,150,000, contrasting with a net cash generated of HK$ 5,233,000 in the same period last year[26]. - Net cash used in financing activities was HK$15,436,000 for the six months ended September 30, 2024, compared to HK$2,548,000 in the same period of 2023[28]. - Cash and cash equivalents at the end of the period were HK$91,285,000, down from HK$132,507,000 at the end of the same period in 2023[28]. - The net cash from investing activities was HK$4,174,000, a significant improvement from a net cash used of HK$1,132,000 in the previous year[28]. Share Capital and Dividends - The Board does not recommend the payment of an interim dividend for the Reporting Period[8]. - A total of 22,177,419 ordinary shares were issued at a subscription price of HK$0.992 per share, completed on April 22, 2024, increasing the issued share capital to HK$5,222,000[81]. - The gross proceeds from the issue of Subscription Shares amounted to HK$22.0 million, with net proceeds of approximately HK$21.8 million after expenses[163]. Segment Performance - The Group's revenue from the IRO with CRO and in-house R&D business segment was approximately HK$28.5 million, representing an increase of approximately 60.1% compared to HK$17.8 million for the six months ended September 30, 2023[107]. - The gross profit for the IRO with CRO segment was approximately HK$5.6 million, a significant improvement from a loss of approximately HK$6.9 million in the previous period[107]. - The Group's gross profit from IRO with CRO and In-house R&D Business increased to approximately HK$5.6 million, a significant recovery from a gross loss of approximately HK$6.9 million[143]. Strategic Initiatives - The Group aims to expand its IRO business to provide synergy for the in-house R&D and healthcare products business units[104]. - The Group plans to implement stringent cost control measures to minimize risks and provide sustainable growth, including reducing manufacturing and administrative costs[182]. - The company is committed to deepening its understanding of customer preferences and designing products that drive long-term sustainable growth, offering competitively priced products to adapt to changing consumer spending patterns[186]. - The company is actively reviewing and adjusting its business strategy to adapt to a challenging business environment[188]. Market Outlook - The demand for healthcare products in the PRC is expected to increase, prompting the Group to focus on achieving better results in this segment[184]. - In the healthcare sector, the company anticipates an increase in demand for healthcare products in China post-2024 and is focusing on enhancing performance and developing new sales structures and business models[187].
EPS创健科技(03860) - 2025 - 中期财报